Evidence map›Paper›PMID 33725350›Full record

ReviewAdvances in experimental medicine and biology2021

Toward a New Era for the Management of Circulating Tumor Cells.

Marisol Miranda Galvis, Celeste Sánchez Romero, Thiago Oliveira Bueno, Yong Teng

Open access · greenAbstract readReview
In one paragraph

Review in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Circulating tumor cells in pancreatic cancer: more than liquid biopsy.Therapeutic advances in medical oncology · 2024
    Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 3 countries.

Marisol Miranda Galvis *Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, GA, USA. mgalvis@augusta.edu.
Celeste Sánchez Romero *Molecular Pathology, Faculty of Dentistry, Universidad de la República (UDELAR), Montevideo, Uruguay.
Thiago Oliveira BuenoClinical Oncology Department, A.C. Camargo Cancer Center, São Paulo, Brazil.
Yong TengDepartment of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, GA, USA. yteng@augusta.edu.
Augusta University · USAC Camargo Hospital · BRUniversidad de la República · UY

Funding

ATAD3A as a Novel Target in Head and Neck CancerR01DE028351 · NIDCR · EMORY UNIVERSITY · PI TENG, YONG · 2019 to 2023
$1.9M
The Impact of Arf1 on Hypoxia Signaling and Oral CancerR03DE028387 · NIDCR · EMORY UNIVERSITY · PI TENG, YONG · 2019 to 2020
$306k
NIDCR NIH HHS R01 DE028351NIDCR NIH HHS R03 DE028387
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) are malignant cells separate from primary tumors, which can migrate through the peripheral blood, colonize other tissues, and lead to the formation of metastases. The first description of CTCs dates back to 1869 when Thomas Ashworth recognized malignant cells similar to the ones of the primary tumor in the blood vessels of an autopsied patient with metastatic cancer. Currently, CTCs have been identified in various types of cancer and have been recognized for their clinical value in the prediction of prognosis, diagnosis of minimal residual diseases, assessment of tumor sensitivity to anticancer drugs, and personalization of therapies. However, research about these topics has several limitations, principally the rarity of CTCs in bloodstream and their heterogeneous characteristics, which makes detection and isolation difficult. As a result of these limitations, current studies are focused on improvement of isolation and characterization techniques to achieve better sensitivity in clinical applications. This review covers the methods of CTC isolation and detection and current research progression on CTC in different cancer types. The clinical applications, limitations, and perspectives of CTCs are also discussed.

Indexed as

Antineoplastic AgentsNeoplastic Cells, CirculatingBiomarkers, TumorCell CountHumansNeoplasm MetastasisAntineoplastic AgentsBiomarkers, TumorCancerCirculating tumor cellsLiquid biopsyMetastasisMicrometastases

Identifiers

PMID33725350
PMCPMC8647934
OpenAlexW3139239774

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.